Hidden dangers of IPO outbreak in the biotechnology market in the first quarter of 2021 still exist

Judging from the IPO data from the beginning of 2021 to the present, private biopharmaceutical companies who are worried about missing listing opportunities can rest assured, because the first quarter of this year, both in terms of the number of listings and the amount of financing, are huge, indicating that market opportunities are still open.

As the situation in the stock market deteriorates, the second quarter of this year may become the key to measuring the bio-capital market for the rest of 2021.

Judging from the data in the first quarter of this year, it did not show any signs of tightening.

Biotechnology IPOs raised a total of US$4.

This analysis from Evaluate, a market consulting company in the life sciences industry, only involves pure drug development companies, excluding medical technology, diagnostics, and digital health.

Recently, the risks of drug development have been lingering in the minds of investors: mainly due to concerns that the US FDA will adopt new and strict review regulations, coupled with the proposed international prohibition of corporate anti-competitive mergers, all have led to nervousness in the open market.

Whether these concerns will have a knock-on effect on the IPO market is still an open question.

Not only that, many companies have successfully maintained this enthusiasm.

The largest IPO in the first quarter was Sana Biotechnology, a company backed by Hans Bishop (Hans Bishop), which successfully raised $676 million in its expanded IPO.

If the financing market continues to maintain its current rapid growth for the rest of this year, 2021 will become another record-breaking year.

But given that the market seems to be turning, this is a big idea, let us wait and see.